Safety and efficacy trial of adipose-tissue derived oral preparation V-6 Immunitor (V-6): results of open-label, two-month, follow-up study

BACKGROUND: Chronic inflammations, atherosclerosis and obesity, are major risk factors for cardiovascular diseases. Immune modulation of the inflammatory response has shown promise in animal models of atherogenesis and metabolic disease. Tableted dietary supplement, V-6, containing pooled antigens d...

Descripción completa

Detalles Bibliográficos
Autores principales: Bourinbaiar, Aldar S, Jirathitikal, Vichai
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2010
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2823747/
https://www.ncbi.nlm.nih.gov/pubmed/20122177
http://dx.doi.org/10.1186/1476-511X-9-14

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2823747/
https://www.ncbi.nlm.nih.gov/pubmed/20122177
http://dx.doi.org/10.1186/1476-511X-9-14

Ejemplares similares